Archives

img-01

Japan’s Medical Device Regulations: A 2025 Update

Over the past year, Japan’s regulatory and reimbursement environment for medical devices has been rapidly changing. These changes illustrate the government’s ongoing commitment to healthcare innovation, effective reimbursement mechanisms, and expanded oversight under the updated Pharmaceutical and Medical Device Act (PMD Act).... Read More

img-01

Quick Japan Regulatory Updates

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the entry of 11 new drugs into the National Health Insurance (NHI) reimbursement system effective May 21, 2025. The newly listed drugs include BeiGene’s cancer immunotherapy Tevimbra (tislelizumab), Servier’s Tibsovo (ivosidenib) for... Read More

img-01

Japan Starts to Utilize AI to Boost Pharma

Japan’s 2025 AI Bill highlights a regulatory change that values innovation rather than restriction, specifically in the pharmaceutical industry. In contrast with the EU’s rule-based system, Japan promotes voluntary compliance and collaboration, with flexible guidelines that speed up drug development. While this... Read More